$BCAB
BioAtla, Inc. Stock $bcab

$bcab Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000095017022002303 Filed on February 28, 2022

Income Statement

Concept	2021 Q4	2021 Q1	2021
Revenue	$0.00	$0.00	$300.0K
YoY Change		-100.0%	-30.23%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.040M	$8.370M	$38.42M
YoY Change	17.92%	-1919.57%	262.42%
% of Gross Profit
Research & Development	$16.45M	$10.42M	$58.27M
YoY Change	56.8%	527.51%	192.35%
% of Gross Profit
Depreciation & Amortization	$314.0K	$309.0K	$1.330M
YoY Change	8.28%	43.06%	31.94%
% of Gross Profit
Operating Expenses	$23.49M	$18.80M	$96.69M
YoY Change	42.7%	1469.03%	216.73%
Operating Profit		-$18.80M	-$96.44M
YoY Change		1594.95%	220.41%
Interest Expense	$96.00K	$2.000K	$3.000K
YoY Change	60.0%	-99.63%	-99.78%
% of Operating Profit
Other Income/Expense, Net	$2.000K	$96.00K	$1.038M
YoY Change		-119.39%	-118.04%
Pretax Income	-$23.39M	-$18.70M	-$95.40M
YoY Change	42.62%	1068.75%	166.11%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$23.39M	-$18.70M	-$95.40M
YoY Change	42.62%	1065.9%	166.09%
Net Earnings / Revenue			-31800.67%
Basic Earnings Per Share			-$2.76
Diluted Earnings Per Share	-$632.3K	-$555.6K	-$2.760M
COMMON SHARES
Basic Shares Outstanding			34.56M
Diluted Shares Outstanding			34.56M

Balance Sheet

Concept	2021 Q4	2021 Q1	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$245.0M	$221.2M	$245.0M
YoY Change	2.67%		2.67%
Cash & Equivalents	$245.0M	$221.2M	$245.0M
Short-Term Investments
Other Short-Term Assets	$2.313M	$3.400M	$2.313M
YoY Change	10.14%		10.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$247.3M	$224.6M	$247.3M
YoY Change	2.75%		2.74%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.676M	$4.351M	$6.976M
YoY Change	-10.39%		70.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$154.0K	$154.0K	$154.0K
YoY Change	0.0%		-23.0%
Total Long-Term Assets	$7.130M	$4.505M	$7.130M
YoY Change	67.53%		69.76%
TOTAL ASSETS
Total Short-Term Assets	$247.3M	$224.6M	$247.3M
Total Long-Term Assets	$7.130M	$4.505M	$7.130M
Total Assets	$254.4M	$229.1M	$254.4M
YoY Change	3.87%		3.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.179M	$2.505M	$1.179M
YoY Change	-52.0%		-52.84%
Accrued Expenses	$4.060M	$800.0K	$4.060M
YoY Change	45.0%		45.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$19.81M	$30.53M	$19.81M
YoY Change	-38.59%		-38.66%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$700.0K	$0.00
YoY Change	-100.0%		-100.0%
Other Long-Term Liabilities	$23.79M	$2.000M	$23.79M
YoY Change	1089.4%		1089.4%
Total Long-Term Liabilities	$23.79M	$2.700M	$23.79M
YoY Change	781.04%		781.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.81M	$30.53M	$19.81M
Total Long-Term Liabilities	$23.79M	$2.700M	$23.79M
Total Liabilities	$43.60M	$33.17M	$43.60M
YoY Change	24.71%		24.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$186.3M	-$109.6M
YoY Change	104.93%
Common Stock	$4.000K	$3.000K
YoY Change	33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$210.8M	$195.9M	$210.8M
YoY Change
Total Liabilities & Shareholders Equity	$254.4M	$229.1M	$254.4M
YoY Change	3.87%		3.89%

Cashflow Statement

Concept	2021 Q4	2021 Q1	2021
OPERATING ACTIVITIES
Net Income	-$23.39M	-$18.70M	-$95.40M
YoY Change	42.62%	1065.9%	166.09%
Depreciation, Depletion And Amortization	$314.0K	$309.0K	$1.330M
YoY Change	8.28%	43.06%	31.94%
Cash From Operating Activities	-$20.95M	-$14.99M	-$62.21M
YoY Change	49.64%	293.13%	71.23%
INVESTING ACTIVITIES
Capital Expenditures	-$89.00K	-$500.0K	-$924.0K
YoY Change	-77.18%	-2600.0%	56.61%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$89.00K	-$501.0K	-$924.0K
YoY Change	-77.18%	2405.0%	56.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$70.99M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-3.908M	-1.911M	69.51M
YoY Change	-101.99%	-482.2%	-74.43%
NET CHANGE
Cash From Operating Activities	-20.95M	-14.99M	-62.21M
Cash From Investing Activities	-89.00K	-501.0K	-924.0K
Cash From Financing Activities	-3.908M	-1.911M	69.51M
Net Change In Cash	-24.95M	-17.41M	6.374M
YoY Change	-113.72%	422.08%	-97.29%
FREE CASH FLOW
Cash From Operating Activities	-$20.95M	-$14.99M	-$62.21M
Capital Expenditures	-$89.00K	-$500.0K	-$924.0K
Free Cash Flow	-$20.86M	-$14.49M	-$61.29M
YoY Change	53.27%	278.04%	71.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-39787
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	bcab	Collaboration Agreement Start Date CollaborationAgreementStartDate	2019-12
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001826892
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Entity Registrant Name EntityRegistrantName	BIOATLA, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1922320
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	11085 Torreyana Road
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2021	dei	City Area Code CityAreaCode	858
CY2021	dei	Local Phone Number LocalPhoneNumber	558-0708
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2021	dei	Trading Symbol TradingSymbol	BCAB
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	1000000000.0
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	San Diego, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	244979000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	238605000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2313000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2076000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	247292000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	240681000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3676000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4102000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3300000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	154000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	154000
CY2021Q4	us-gaap	Assets Assets	254422000
CY2020Q4	us-gaap	Assets Assets	244937000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	18424000
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12068000
CY2021Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	0
CY2020Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	387000
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	19806000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1389000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19813000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32261000
CY2021Q4	bcab	Long Term Accrued Interest LongTermAccruedInterest	0
CY2020Q4	bcab	Long Term Accrued Interest LongTermAccruedInterest	5000
CY2021Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0
CY2020Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	2015000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19933000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25919000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38416000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10595000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7549000
CY2021	us-gaap	Operating Expenses OperatingExpenses	96690000
CY2020	us-gaap	Operating Expenses OperatingExpenses	30528000
CY2019	us-gaap	Operating Expenses OperatingExpenses	33468000
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-96440000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3982000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2021Q4	bcab	Liability To Licensor LiabilityToLicensor	19806000
CY2020Q4	bcab	Liability To Licensor LiabilityToLicensor	0
CY2021Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	0
CY2020Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	682000
CY2021Q4	us-gaap	Liabilities Liabilities	43601000
CY2020Q4	us-gaap	Liabilities Liabilities	34963000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35799233
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35799233
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32171560
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32171560
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	397136000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	300888000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-186319000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-90917000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	210821000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	209974000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	254422000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	244937000
CY2021	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	250000
CY2020	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	429000
CY2019	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	5200000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	58274000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-30099000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-28268000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	350000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	100000
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	128000
CY2021	us-gaap	Interest Expense InterestExpense	3000
CY2020	us-gaap	Interest Expense InterestExpense	1389000
CY2019	us-gaap	Interest Expense InterestExpense	1630000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1581000
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	63000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	690000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2883000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	bcab	Other Income Expense OtherIncomeExpense	1000
CY2020	bcab	Other Income Expense OtherIncomeExpense	-1000
CY2019	bcab	Other Income Expense OtherIncomeExpense	-22000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1038000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5754000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1587000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-95402000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-35853000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-29855000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-61000
CY2021	bcab	Net Income Loss Consolidated Net Loss And Comprehensive Loss NetIncomeLossConsolidatedNetLossAndComprehensiveLoss	-95402000
CY2020	bcab	Net Income Loss Consolidated Net Loss And Comprehensive Loss NetIncomeLossConsolidatedNetLossAndComprehensiveLoss	-35853000
CY2019	bcab	Net Income Loss Consolidated Net Loss And Comprehensive Loss NetIncomeLossConsolidatedNetLossAndComprehensiveLoss	-29794000
CY2019	bcab	Net Income Loss Allocable To Class C Preferred Unit Holders NetIncomeLossAllocableToClassCPreferredUnitHolders	9089000
CY2019	bcab	Preferred Return On Class Adjsutments Increase Decrease PreferredReturnOnClassAdjsutmentsIncreaseDecrease	8026000
CY2019	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-28731000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.76
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.19
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34561245
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8428153
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-28446000
CY2019	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	5000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	764000
CY2019	bcab	Assumption Of Unvested Profits Interest Liability By Affiliates AssumptionOfUnvestedProfitsInterestLiabilityByAffiliates	197000
CY2019	bcab	Assumption Of Vested Profits Interest Liability By Affiliates AssumptionOfVestedProfitsInterestLiabilityByAffiliates	800000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	534000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-29855000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-56011000
CY2020	bcab	Assumption Of Profit Interest Liability By Affiliate AssumptionOfProfitInterestLiabilityByAffiliate	991000
CY2020	bcab	Change In Profits Interest Liability Of Affiliate ChangeInProfitsInterestLiabilityOfAffiliate	749000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-35853000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	209974000
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4007000
CY2020	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	19000
CY2020	bcab	Stock Issued During Period Value Conversion Of Convertible Preferred Stock Into Common Stock StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockIntoCommonStock	98777000
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	19032000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	198318000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3022000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-95402000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-35853000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-29855000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1330000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1008000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	860000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	140000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	289000
CY2021	bcab	Tax Related To Net Settlement Of Equity Awards Included In Accounts Payable And Accrued Expenses TaxRelatedToNetSettlementOfEquityAwardsIncludedInAccountsPayableAndAccruedExpenses	-291000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25117000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-95402000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	210821000
CY2020	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	0
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	70994000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-4000
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-0
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-3000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-1581000
CY2019	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-63000
CY2021	bcab	Change In Fair Value And Pushdown Of Profits Interest Liability ChangeInFairValueAndPushdownOfProfitsInterestLiability	0
CY2020	bcab	Change In Fair Value And Pushdown Of Profits Interest Liability ChangeInFairValueAndPushdownOfProfitsInterestLiability	6852000
CY2019	bcab	Change In Fair Value And Pushdown Of Profits Interest Liability ChangeInFairValueAndPushdownOfProfitsInterestLiability	6403000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	690000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2883000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	25117000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	3022000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	0
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	0
CY2020	us-gaap	Paid In Kind Interest PaidInKindInterest	525000
CY2019	us-gaap	Paid In Kind Interest PaidInKindInterest	355000
CY2021	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-3000
CY2020	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-864000
CY2019	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-1276000
CY2021	bcab	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0
CY2020	bcab	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	150000
CY2019	bcab	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-230000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	237000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1273000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-939000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	7992000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1660000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3218000
CY2021	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	0
CY2019	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-88000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-429000
CY2019	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	19757000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-331000
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0
CY2019	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-62214000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36334000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9645000
CY2021	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	924000
CY2020	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	590000
CY2019	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	1509000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-924000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-590000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1509000
CY2021	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	0
CY2020	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	19000
CY2019	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	5000
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0
CY2020	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	2750000
CY2019	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	4000000
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0
CY2020	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	68183000
CY2019	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0
CY2021	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	0
CY2020	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	682000
CY2019	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	0
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	200229000
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
CY2021	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	1911000
CY2020	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	0
CY2019	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	0
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	70994000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	140000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	289000
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	0
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	0
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	69512000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	271825000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3995000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	6374000
CY2020	bcab	Assumption Of Profits Interest Liability By Affiliates AssumptionOfProfitsInterestLiabilityByAffiliates	991000
CY2019	bcab	Assumption Of Profits Interest Liability By Affiliates AssumptionOfProfitsInterestLiabilityByAffiliates	997000
CY2021	bcab	Equity Issuance Costs Included In Accounts Payable And Accrued Expenses EquityIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses	0
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	234901000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-7159000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	238605000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3704000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10863000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	244979000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	238605000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3704000
CY2021	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	1000
CY2020	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	17000
CY2019	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	172000
CY2021	bcab	Fair Value Of Warrants Issued By Affiliates In Connection With Modification Of Convertible Promissory Notes FairValueOfWarrantsIssuedByAffiliatesInConnectionWithModificationOfConvertiblePromissoryNotes	0
CY2020	bcab	Fair Value Of Warrants Issued By Affiliates In Connection With Modification Of Convertible Promissory Notes FairValueOfWarrantsIssuedByAffiliatesInConnectionWithModificationOfConvertiblePromissoryNotes	0
CY2019	bcab	Fair Value Of Warrants Issued By Affiliates In Connection With Modification Of Convertible Promissory Notes FairValueOfWarrantsIssuedByAffiliatesInConnectionWithModificationOfConvertiblePromissoryNotes	764000
CY2021	bcab	Assumption Of Profits Interest Liability By Affiliates AssumptionOfProfitsInterestLiabilityByAffiliates	0
CY2020	bcab	Equity Issuance Costs Included In Accounts Payable And Accrued Expenses EquityIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses	1911000
CY2019	bcab	Equity Issuance Costs Included In Accounts Payable And Accrued Expenses EquityIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses	0
CY2021	bcab	Carrying Value Of Convertible Promissory Notes Settled In Connection With Corporate Reorganization CarryingValueOfConvertiblePromissoryNotesSettledInConnectionWithCorporateReorganization	0
CY2020	bcab	Carrying Value Of Convertible Promissory Notes Settled In Connection With Corporate Reorganization CarryingValueOfConvertiblePromissoryNotesSettledInConnectionWithCorporateReorganization	27711000
CY2019	bcab	Carrying Value Of Convertible Promissory Notes Settled In Connection With Corporate Reorganization CarryingValueOfConvertiblePromissoryNotesSettledInConnectionWithCorporateReorganization	0
CY2021	bcab	Fair Value Of Consideration Issued In Connection With Settlement Of Convertible Promissory Notes FairValueOfConsiderationIssuedInConnectionWithSettlementOfConvertiblePromissoryNotes	0
CY2020	bcab	Fair Value Of Consideration Issued In Connection With Settlement Of Convertible Promissory Notes FairValueOfConsiderationIssuedInConnectionWithSettlementOfConvertiblePromissoryNotes	30594000
CY2019	bcab	Fair Value Of Consideration Issued In Connection With Settlement Of Convertible Promissory Notes FairValueOfConsiderationIssuedInConnectionWithSettlementOfConvertiblePromissoryNotes	0
CY2021	bcab	Tax Related To Net Settlement Of Equity Awards Included In Accounts Payable And Accrued Expenses TaxRelatedToNetSettlementOfEquityAwardsIncludedInAccountsPayableAndAccruedExpenses	-291000
CY2020	bcab	Tax Related To Net Settlement Of Equity Awards Included In Accounts Payable And Accrued Expenses TaxRelatedToNetSettlementOfEquityAwardsIncludedInAccountsPayableAndAccruedExpenses	0
CY2019	bcab	Tax Related To Net Settlement Of Equity Awards Included In Accounts Payable And Accrued Expenses TaxRelatedToNetSettlementOfEquityAwardsIncludedInAccountsPayableAndAccruedExpenses	0
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	bcab	Company Formation Date CompanyFormationDate	2007-03
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6220050
CY2020Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-13
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Risk</span></p><p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p><p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">For the years ended December 31, 2021, 2020, and 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">, BeiGene, as defined and described in Note 9, represented </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%, </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">% and </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">91</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%, respectively, of total revenues.</span></p>
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company’s consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of the Company’s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to revenue recognition, accruals for research and development costs, equity-based compensation and fair value measurements. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span></p>
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	us-gaap	Revenue Recognition Revenue Reductions RevenueRecognitionRevenueReductions	<p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span></p><p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:5.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration the Company is entitled to receive in exchange for such product or service. In doing so, the Company follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. The Company considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard.</span></p><p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">A customer is a party that has entered into a contract with the Company, where the purpose of the contract is to obtain a product or a service that is an output of the Company’s ordinary activities in exchange for consideration. To be considered a contract, (i) the contract must be approved (in writing, orally, or in accordance with other customary business practices), (ii) each party’s rights regarding the product or the service to be transferred can be identified, (iii) the payment terms for the product or the service to be transferred can be identified, (iv) the contract must have commercial substance (that is, the risk, timing or amount of future cash flows is expected to change as a result of the contract), and (v) it is probable that the Company will collect substantially all of the consideration to which it is entitled to receive in exchange for the transfer of the product or the service.</span></p><p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">A performance obligation is defined as a promise to transfer a product or a service to a customer. The Company identifies each promise to transfer a product or a service (or a bundle of products or services, or a series of products and services that are substantially the same and have the same pattern of transfer) that is distinct. A product or a service is distinct if both (i) the customer can benefit from the product or the service either on its own or together with other resources that are readily available to the customer and (ii) the Company’s promise to transfer the product or the service to the customer is separately identifiable from other promises in the contract. Each distinct promise to transfer a product or a service is a unit of accounting for revenue recognition. If a promise to transfer a product or a service is not separately identifiable from other promises in the contract, such promises should be combined into a single performance obligation.</span></p><p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The transaction price is the amount of consideration the Company is entitled to receive in exchange for the transfer of control of a product or a service to a customer. To determine the transaction price, the Company considers the existence of any significant financing component, the effects of any variable elements, noncash consideration and consideration payable to the customer. If a significant financing component exists, the transaction price is adjusted for the time value of money. If an element of variability exists, the Company must estimate the consideration it expects to receive and uses that amount as the basis for recognizing revenue as the product or the service is transferred to the customer. There are two methods for determining the amount of variable consideration: (i) the expected value method, which is the sum of probability-weighted amounts in a range of possible consideration amounts, and (ii) the mostly likely amount method, which identifies the single most likely amount in a range of possible consideration amounts.</span></p><p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If a contract has multiple performance obligations, the Company allocates the transaction price to each distinct performance obligation in an amount that reflects the consideration the Company is entitled to receive in exchange for satisfying each distinct performance obligation. For each distinct performance obligation, revenue is recognized when the Company transfers control of the product or the service applicable to such performance obligation.</span></p><p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">In those instances where the Company first receives consideration in advance of satisfying its performance obligation, the Company classifies such consideration as deferred revenue until (or as) the Company satisfies such performance obligation. In those instances where the Company first satisfies its performance obligation prior to its receipt of consideration, the consideration is recorded as accounts receivable.</span></p><p style="margin-left:2.32%;text-indent:4.177%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The Company expenses incremental costs of obtaining and fulfilling a contract as incurred if the expected amortization period of the asset that would be recognized is one year or less, or if the amount of the asset is immaterial. Otherwise, such costs are capitalized as contract assets if they are incremental to the contract and amortized to expense proportionate to revenue recognition of the underlying contract.</span></p>
CY2021Q4	bcab	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	6200000
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4100000
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1100000
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5400000
CY2021Q4	bcab	Uncertain Tax Positions Percentage UncertainTaxPositionsPercentage	0.50
CY2021	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.10
	us-gaap	Net Income Loss NetIncomeLoss	-26877000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8428153
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.19
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2213036
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3252817
CY2021Q4	bcab	Prepaid Research And Development Expense PrepaidResearchAndDevelopmentExpense	1811000
CY2020Q4	bcab	Prepaid Research And Development Expense PrepaidResearchAndDevelopmentExpense	2004000
CY2021Q4	bcab	Other Prepaid Expenses And Current Assets OtherPrepaidExpensesAndCurrentAssets	502000
CY2020Q4	bcab	Other Prepaid Expenses And Current Assets OtherPrepaidExpensesAndCurrentAssets	72000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2313000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2076000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7933000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7172000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4257000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3070000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3676000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4102000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1179000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2456000
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2671000
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2804000
CY2021Q4	bcab	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	13501000
CY2020Q4	bcab	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	4852000
CY2021Q4	bcab	Accrued Equity Issuance Costs Current AccruedEquityIssuanceCostsCurrent	0
CY2020Q4	bcab	Accrued Equity Issuance Costs Current AccruedEquityIssuanceCostsCurrent	1143000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1073000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	813000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	18424000
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12068000
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	0
CY2020Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	0
CY2021Q4	us-gaap	Derivative Asset Fair Value Gross Liability DerivativeAssetFairValueGrossLiability	0
CY2020Q4	us-gaap	Derivative Asset Fair Value Gross Liability DerivativeAssetFairValueGrossLiability	0
CY2019Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	1856000
CY2020	bcab	Embedded Derivative Initial Fair Value Of Embedded Derivatives Issued EmbeddedDerivativeInitialFairValueOfEmbeddedDerivativesIssued	3415000
CY2020	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	1581000
CY2020	bcab	Embedded Derivative Liability Settlement EmbeddedDerivativeLiabilitySettlement	-6852000
CY2020Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	0
CY2018Q2	us-gaap	Debt Conversion Description DebtConversionDescription	The 2018 Notes were amended in April 2020 to add a discount to the conversion prices such that they were convertible (i) automatically into preferred stock upon a qualified equity financing, with a conversion price of 80% of the lowest purchase price per share of preferred stock paid by investors in such qualified equity financing, (ii) automatically convert into common stock upon an initial public offering, with a conversion price of 80% of the price per share of common stock paid by investors in such initial public offering, and (iii) upon the election of each note holder, into Class C preferred units, with a conversion price per share of $2.7153136.
CY2019	us-gaap	Debt Conversion Description DebtConversionDescription	The 2019 Notes were convertible (i) automatically into preferred stock upon a qualified equity financing, with a conversion price of 80% of the lowest purchase price per share of preferred stock paid by investors in such qualified equity financing, (ii) automatically into common stock upon an initial public offering, with a conversion price of 80% of the price per share of common stock paid by investors in such initial public offering, and (iii) upon the election of each note holder, into Class C preferred units, with a conversion price per share of $2.7153136.
CY2021	us-gaap	Lessor Operating Lease Option To Extend LessorOperatingLeaseOptionToExtend	The lease expires in July 2025 and the Company has an option to extend the term of the lease for an additional five years. However, it is not reasonably certain the Company will exercise the option to renew when the lease term ends and thus, the incremental term was excluded from the calculation of the lease liability. Additionally, the
CY2021	bcab	Lessor Operating Leases Option To Extend LessorOperatingLeasesOptionToExtend	P5Y
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3300000
CY2021Q4	bcab	Operating Lease Right Of Use Asset Total OperatingLeaseRightOfUseAssetTotal	3300000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1389000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3982000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5371000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1043000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	512000
CY2021	us-gaap	Lease Cost LeaseCost	1555000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0350
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1374000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1555000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1636000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1685000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	845000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5721000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	350000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5371000
CY2020Q4	bcab	Lessee Operating Lease Liability Minimum Payments Due In Twelve Months LesseeOperatingLeaseLiabilityMinimumPaymentsDueInTwelveMonths	1374000
CY2020Q4	bcab	Lessee Operating Lease Liability Minimum Payments Due In Two Years LesseeOperatingLeaseLiabilityMinimumPaymentsDueInTwoYears	1555000
CY2020Q4	bcab	Lessee Operating Lease Liability Minimum Payments Due In Three Years LesseeOperatingLeaseLiabilityMinimumPaymentsDueInThreeYears	1636000
CY2020Q4	bcab	Lessee Operating Lease Liability Minimum Payments Due In Four Years LesseeOperatingLeaseLiabilityMinimumPaymentsDueInFourYears	1685000
CY2020Q4	bcab	Lessee Operating Lease Liability Payments Due Thereafter LesseeOperatingLeaseLiabilityPaymentsDueThereafter	845000
CY2020Q4	bcab	Lessee Operating Lease Liability Minimum Payments Due LesseeOperatingLeaseLiabilityMinimumPaymentsDue	7095000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	1700000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	1100000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	Holders of the Company’s common stock have no conversion rights, while holders of the Company’s Class B common stock shall have the right to convert each share of Class B common stock into one share of common stock at such holder’s election, provided that as a result of such conversion, such holder would not beneficially own in excess of 4.99% of any class of the Company’s securities registered under the Securities Exchange Act of 1934
CY2021	bcab	Period Related To Changing Of Ownership Limitation Percentage Designated By Class B Common Stock Holder PeriodRelatedToChangingOfOwnershipLimitationPercentageDesignatedByClassBCommonStockHolder	P61D
CY2021	bcab	Warrants Expired And Unexercised WarrantsExpiredAndUnexercised	566586
CY2018Q4	bcab	Annual Rate Of Purchase Price Per Share AnnualRateOfPurchasePricePerShare	0.07
CY2020	bcab	Net Loss Of Htky Allocated To Noncontrolling Interest NetLossOfHTKYAllocatedToNoncontrollingInterest	61000000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1900000
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	693000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1449000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	837000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	25117000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	3022000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y11M12D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	479543
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	37.86
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	7747
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	18.00
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	182829000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	26.76
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y2M19D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	991495000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1086902
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	26.76
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y2M19D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	991495000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	155579
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	18.31
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y11M19D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	247486000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M23D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M2D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.747
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.745
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0106
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0052
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6247701
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6122181
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14478949
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	170836
CY2020	bcab	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsShares	14308113
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	33400000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	20600000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	485000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	585000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5607000
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	4159000
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	3449000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	504000
CY2021Q4	bcab	Lease Liability LeaseLiability	1128000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	438000
CY2020Q4	bcab	Deferred Tax Assets Guaranteed Payments DeferredTaxAssetsGuaranteedPayments	1702000
CY2021Q4	us-gaap	Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Bad Debt Reserve For Tax Purposes Of Qualified Lender DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityBadDebtReserveForTaxPurposesOfQualifiedLender	4159000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	6158328
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	170836
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1310807
CY2020	bcab	Share Based Compensation Arrangement By Share Based Payment Award Unvested Fair Value Assumptions Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardUnvestedFairValueAssumptionsShares	4676685
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	0
CY2019	bcab	Reduction To Aggregate Profits Interest Liability ReductionToAggregateProfitsInterestLiability	-900000
CY2019	bcab	Increase Decrease In Profits Interest Liability IncreaseDecreaseInProfitsInterestLiability	-7400000
CY2019Q4	bcab	Fair Value Of Profit Interest Liability FairValueOfProfitInterestLiability	8592000
CY2020	bcab	Increase Decrease In Fair Value Of Vested Liability Stock Based Compensation Expense IncreaseDecreaseInFairValueOfVestedLiabilityStockBasedCompensationExpense	-7601000
CY2020	bcab	Fair Value Of Vested Liability Assumed Additional Paid In Capital FairValueOfVestedLiabilityAssumedAdditionalPaidInCapital	-991000
CY2020Q4	bcab	Fair Value Of Profit Interest Liability FairValueOfProfitInterestLiability	0
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	-6852000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	-6403000
CY2019	bcab	Upfront Non Refundable Payment UpfrontNonRefundablePayment	20000000.0
CY2019	bcab	Agreement Transaction Price AgreementTransactionPrice	25000000.0
CY2021	us-gaap	Revenues Revenues	300000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2945000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	610000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	697000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	34800000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	13605000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	21935000
CY2021	us-gaap	Related Party Transaction Terms And Manner Of Settlement RelatedPartyTransactionTermsAndMannerOfSettlement	On March 18, 2021, the Company and Carolyn Anderson Short, its co-founder and former Chief of Intellectual Property & Strategy, mutually agreed that Ms. Short would depart the Company on May 31, 2021 following an agreed upon transition period. The Transition Agreement provides for the following severance benefits in exchange for a release of claims by Ms. Short: (i) a lump sum payment equal to eighteen (18) months of Ms. Short’s current base salary, (ii) a payment at her targeted bonus rate for 2021, pro-rated to the separation date, and (iii) accelerated full vesting of her equity awards including 7,747 stock options and 138,461 restricted stock units. The modification of these equity awards resulted in an incremental fair value of $7.0 million which was recognized on a straight-line basis over the transition service period. For the twelve months ended December 31, 2021, the Company recognized $1.0 million related to the lump sum salary payment and target bonus. The Company also recognized non-cash stock-based compensation charges of $9.4 million related to the modified equity awards for the twelve months ended December 31, 2021. No unrecognized stock-based compensation remained as of December 31, 2021. Ms. Short exercised her 7,747 stock options in 2021, therefore there are no remaining options outstanding related to Ms. Short’s transition agreement as of December 31, 2021.
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0
CY2019Q4	bcab	License Fees LicenseFees	10000
CY2019Q4	us-gaap	Stock Granted During Period Value Sharebased Compensation Forfeited StockGrantedDuringPeriodValueSharebasedCompensationForfeited	25000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-20034000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7529000
CY2021	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-2131000
CY2020	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-6708000
CY2020	bcab	Partnership Income Not Subject To Tax PartnershipIncomeNotSubjectToTax	1837000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	4145000
CY2021	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	1021000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	3091000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	807000
CY2021	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	757000
CY2020	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	197000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	793000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	242000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	20582000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	12768000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	33351000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12768000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1449000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	837000
CY2021Q4	us-gaap	Deferred Tax Liabilities Regulatory Assets DeferredTaxLiabilitiesRegulatoryAssets	756000
CY2020Q4	us-gaap	Deferred Tax Liabilities Regulatory Assets DeferredTaxLiabilitiesRegulatoryAssets	837000
CY2021Q4	bcab	Federal Net Operating Loss Carryforward FederalNetOperatingLossCarryforward	104500000
CY2021	us-gaap	Tax Credit Carryforward Limitations On Use TaxCreditCarryforwardLimitationsOnUse	The federal net operating losses can be carried forward indefinitely, subject to an 80% limitation against taxable income.
CY2021	bcab	Annual Operating Loss Carryforwards Use AnnualOperatingLossCarryforwardsUse	Sections 382 and 383, annual use of the Company’s net operating loss carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period.
CY2021	bcab	Cares Act Nol Carryover Carryback Offset To Taxable Income CaresActNolCarryoverCarrybackOffsetToTaxableIncome	0.50
CY2020Q1	bcab	Cares Act Nol Carryover Carryback Offset To Taxable Income CaresActNolCarryoverCarrybackOffsetToTaxableIncome	1
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	210000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	210000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	801000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1011000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1000000.0

Files In Submission

Name	View Source	Status
0000950170-22-002303-index-headers.html	Edgar Link	pending
0000950170-22-002303-index.html	Edgar Link	pending
0000950170-22-002303.txt	Edgar Link	pending
0000950170-22-002303-xbrl.zip	Edgar Link	pending
bcab-20211231.htm	Edgar Link	pending
bcab-20211231.xsd	Edgar Link	pending
bcab-20211231_cal.xml	Edgar Link	unprocessable
bcab-20211231_def.xml	Edgar Link	unprocessable
bcab-20211231_htm.xml	Edgar Link	completed
bcab-20211231_lab.xml	Edgar Link	unprocessable
bcab-20211231_pre.xml	Edgar Link	unprocessable
bcab-ex10_19.htm	Edgar Link	pending
bcab-ex10_20.htm	Edgar Link	pending
bcab-ex10_21.htm	Edgar Link	pending
bcab-ex10_22.htm	Edgar Link	pending
bcab-ex10_26.htm	Edgar Link	pending
bcab-ex10_27.htm	Edgar Link	pending
bcab-ex10_28.htm	Edgar Link	pending
bcab-ex10_31.htm	Edgar Link	pending
bcab-ex23_1.htm	Edgar Link	pending
bcab-ex31_1.htm	Edgar Link	pending
bcab-ex31_2.htm	Edgar Link	pending
bcab-ex32_1.htm	Edgar Link	pending
bcab-ex4_3.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img65647623_0.jpg	Edgar Link	pending
img65647623_1.jpg	Edgar Link	pending
img65647623_10.jpg	Edgar Link	pending
img65647623_11.jpg	Edgar Link	pending
img65647623_12.jpg	Edgar Link	pending
img65647623_13.jpg	Edgar Link	pending
img65647623_14.jpg	Edgar Link	pending
img65647623_15.jpg	Edgar Link	pending
img65647623_16.jpg	Edgar Link	pending
img65647623_17.jpg	Edgar Link	pending
img65647623_18.jpg	Edgar Link	pending
img65647623_19.jpg	Edgar Link	pending
img65647623_2.jpg	Edgar Link	pending
img65647623_3.jpg	Edgar Link	pending
img65647623_4.jpg	Edgar Link	pending
img65647623_5.jpg	Edgar Link	pending
img65647623_6.jpg	Edgar Link	pending
img65647623_7.jpg	Edgar Link	pending
img65647623_8.jpg	Edgar Link	pending
img65647623_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCAB
BioAtla, Inc. Stock $bcab

2021 Q4 Form 10-K Financial Statement

#000095017022002303 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCAB BioAtla, Inc. Stock $bcab

2021 Q4 Form 10-K Financial Statement

#000095017022002303 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCAB
BioAtla, Inc. Stock $bcab